{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:32:10Z","timestamp":1791844330509,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["280873"],"award-info":[{"award-number":["280873"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.coph.2018.03.014","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:38:26Z","timestamp":1523972306000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Adjuvant strategies to improve vaccination of the elderly population"],"prefix":"10.1016","volume":"41","author":[{"given":"Birgit","family":"Weinberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.03.014_bib0345","first-page":"49","article-title":"Vaccine-preventable diseases, immunizations, and MMWR\u20141961\u20132011","volume":"60","author":"Hinman","year":"2011","journal-title":"MMWR Suppl"},{"key":"10.1016\/j.coph.2018.03.014_bib0350","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1473-3099(02)00437-1","article-title":"Ageing and infection","volume":"2","author":"Gavazzi","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0355","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/529197","article-title":"Biology of immune responses to vaccines in elderly persons","volume":"46","author":"Weinberger","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0360","first-page":"226","article-title":"Pneumonia in the elderly (geriatric) population","volume":"11","author":"Janssens","year":"2005","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coph.2018.03.014_bib0365","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40520-015-0450-0","article-title":"Functional decline and herpes zoster in older people: an interplay of multiple factors","volume":"27","author":"Attal","year":"2015","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.coph.2018.03.014_bib0370","series-title":"World Population Prospects","doi-asserted-by":"crossref","DOI":"10.18356\/b19523c6-en","author":"United Nations","year":"2017"},{"key":"10.1016\/j.coph.2018.03.014_bib0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0380","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59\u2014an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0385","doi-asserted-by":"crossref","first-page":"e0185843","DOI":"10.1371\/journal.pone.0185843","article-title":"Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells","volume":"12","author":"Cioncada","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2018.03.014_bib0390","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","article-title":"Oil-in-water emulsion MF59 increases germinal center B cell differentiation and persistence in response to vaccination","volume":"195","author":"Lofano","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/21645515.2015.1011562","article-title":"Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review","volume":"11","author":"Camilloni","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2018.03.014_bib0400","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2014.11.062","article-title":"Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults","volume":"33","author":"Black","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0405","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2018.03.014_bib0410","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4161\/hv.23239","article-title":"Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines","volume":"9","author":"Orsi","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coph.2018.03.014_bib0415","doi-asserted-by":"crossref","first-page":"15ra5","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2018.03.014_sbref0420","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0425","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immungenicity fo an MF59\u00ae-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_sbref0430","series-title":"Immunopotentiators in Modern Vaccines","first-page":"249","article-title":"MF59: a safe and potent adjuvant for human use","author":"Kommareddy","year":"2017"},{"key":"10.1016\/j.coph.2018.03.014_bib0435","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/CVI.00475-15","article-title":"Persistence of antibody to influenza A\/H5N1 vaccine virus: impact of AS03 adjuvant","volume":"23","author":"Chen","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(10)70296-6","article-title":"Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial","volume":"11","author":"Nicholson","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2018.03.014_bib0450","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: a phase II, observer-blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0455","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1016\/j.vaccine.2017.07.013","article-title":"Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: a phase I\/II randomized trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0460","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","article-title":"Eleven years of inflexal V-a virosomal adjuvanted influenza vaccine","volume":"27","author":"Herzog","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_sbref0465","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coph.2018.03.014_bib0470","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.03.014_sbref0475","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0480","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_sbref0485","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.03.014_sbref0490","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.03.014_bib0495","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.4049\/jimmunol.1600993","article-title":"IL-18 and subcapsular lymph node macrophages are essential for enhanced B cell responses with TLR4 agonist adjuvants","volume":"197","author":"Desbien","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0500","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and Type 1 cellular immune responses with fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0505","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","article-title":"A synthetic adjuvant to enhance and expand immune responses to influenza vaccines","volume":"5","author":"Coler","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.03.014_bib0510","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10522-015-9576-x","article-title":"The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age","volume":"17","author":"Weinberger","year":"2016","journal-title":"Biogerontology"},{"key":"10.1016\/j.coph.2018.03.014_bib0515","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jir769","article-title":"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults","volume":"205","author":"Behzad","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0520","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0525","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.vaccine.2016.04.002","article-title":"A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant","volume":"34","author":"Falloon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0530","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00157-17","article-title":"Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses","volume":"24","author":"Falloon","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coph.2018.03.014_sbref0535","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_sbref0540","doi-asserted-by":"crossref","first-page":"e0188708","DOI":"10.1371\/journal.pone.0188708","article-title":"Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice","volume":"12","author":"Cayatte","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2018.03.014_bib0545","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/CVI.00816-13","article-title":"Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB\/c mice","volume":"21","author":"Zhang","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2018.03.014_bib0550","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Schon","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.03.014_bib0555","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(15)00354-0","article-title":"Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b\/3 trial","volume":"16","author":"Hung","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0560","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.vaccine.2013.10.052","article-title":"Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0565","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0570","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and immunogenicity of multimeric-001\u2014a novel universal influenza vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0575","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1016\/j.vaccine.2017.08.021","article-title":"Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes","volume":"35","author":"Smith","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0585","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/jis330","article-title":"T-helper 1 cells elicited by H5N1 vaccination predict seroprotection","volume":"206","author":"Pedersen","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2018.03.014_bib0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0595","doi-asserted-by":"crossref","first-page":"e0131652","DOI":"10.1371\/journal.pone.0131652","article-title":"Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets","volume":"10","author":"Cox","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2018.03.014_bib0600","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","article-title":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax delta inulin adjuvant","volume":"34","author":"Gordon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coph.2018.03.014_bib0610","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1016\/j.vaccine.2010.04.011","article-title":"Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine","volume":"28","author":"Even-Or","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0615","doi-asserted-by":"crossref","first-page":"e22891","DOI":"10.1371\/journal.pone.0022891","article-title":"CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets","volume":"6","author":"Martel","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.03.014_bib0620","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1016\/j.vaccine.2011.06.040","article-title":"Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes","volume":"29","author":"Rosenkrands","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0625","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3389\/fimmu.2017.01928","article-title":"Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant","volume":"8","author":"Christensen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0630","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0635","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.vaccine.2009.04.054","article-title":"Cationic lipid\/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection","volume":"27","author":"Lay","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0640","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virol.2016.02.024","article-title":"A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets","volume":"492","author":"Liu","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.coph.2018.03.014_bib0645","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12985-017-0698-4","article-title":"The intranasal adjuvant Endocine enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen","volume":"14","author":"Falkeborn","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.coph.2018.03.014_bib0650","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clim.2005.08.016","article-title":"CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB\/c mice","volume":"117","author":"Maletto","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0655","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exger.2014.01.006","article-title":"Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly","volume":"54","author":"Fujihashi","year":"2014","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.coph.2018.03.014_bib0660","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.vaccine.2008.04.029","article-title":"The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice","volume":"26","author":"Riedl","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coph.2018.03.014_bib0665","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","article-title":"Flagellin as an adjuvant: cellular mechanisms and potential","volume":"185","author":"Mizel","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.03.014_bib0670","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/acel.12383","article-title":"Flagellin-dependent TLR5\/caveolin-1 as a promising immune activator in immunosenescence","volume":"14","author":"Lim","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.coph.2018.03.014_sbref0675","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2018.03.014_sbref0680","doi-asserted-by":"crossref","first-page":"39097","DOI":"10.1038\/srep39097","article-title":"Comparative systems analyses reveal molecular signatures of clinically tested vaccine adjuvants","volume":"6","author":"Olafsdottir","year":"2016","journal-title":"Sci Rep"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217302072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217302072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T22:54:25Z","timestamp":1571180065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217302072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":68,"alternative-id":["S1471489217302072"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.014","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant strategies to improve vaccination of the elderly population","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}